Drugs / ChAd63-KH
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04107961 | Oct 2023 → Dec 2024 | cutaneous leishmaniasis | University of York | Withdrawn | No outcome recorded |
| Phase 2 | NCT02894008 | Nov 2016 → Sep 2019 | cutaneous leishmaniasis | University of York | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03969134 Comparator | Apr 2020 → Aug 2022 | cutaneous leishmaniasis | University of York | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAd63-KH | “Leishmania Vaccine ChAd63-KH” NCT04107961 ↗ |
| Modality | Vaccine | “ChAd63-KH vaccine” PMID 33781913 ↗ Mar 2021 |
| Route | Intramuscular | “Patients received a single intramuscular vaccination” PMID 33781913 ↗ Mar 2021 |